Stocks Articles

iX Biopharma Ltd – Gaining altitude with significant approvals

Brief Overview The US Secretary of Health and Human Services (HHS) has declared an Emergency...

25 Sep 2026  |   43 

Palo Alto Networks Inc – Highest Sales Growth in 9 Years

Brief Overview Palo Alto Networks delivered 4Q26 revenue and PATMI results that met expectations, with...

25 Sep 2026  |   20 

Phillip Singapore Monthly: August 2026 – Trading at a Justified Premium

Brief Overview Singapore equities delivered another strong month in August, rising 2.3% for the fifth...

25 Sep 2026  |   15 

Q & M Dental Group Awaits Inorganic Growth Amid Challenging Operating Environment

Brief Overview Q & M Dental Group’s 1H26 results fell short of expectations, with revenue...

25 Sep 2026  |   12 

Singapore Aviation Sector Faces Fuel Price Surge and Margin Pressure

Brief Overview In August 2026, Singapore’s aviation sector experienced significant declines, with SATS dropping 18.5%,...

25 Sep 2026  |   10 

Singapore Banks See Loan Growth Hit 10% as Volume Replaces Margin

Brief Overview Singapore banking shows encouraging momentum with interest rates rising for the fourth consecutive...

25 Sep 2026  |   11 

Apple Launches First Foldable iPhone Amid Pricing and AI Challenges

Brief Overview Apple held its “Surprise and Shine” event on 9 September, launching several new...

22 Sep 2026  |   63 

Beyond The Usual Markets: Discover Kazakhstan

A Closer Look At Kazakhstan As Kazakhstan gains popularity as a travel destination across Central...

17 Sep 2026  |   147 

Get Started Today

Open an Account Enquiry

For assistance, call 6212 1818 | Visit our Phillip Investor Centres

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com